E
IRLA

Ergoteles’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Ergoteles’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-196
Closed -$25K – 1675
2022
Q4 		$25K Buy
+196
New +$32.8K ﹤0.01% 1337
2022
Q3 		– Sell
-490
Closed -$218K – 1900
2022
Q2 		$218K Buy
+490
New +$346K 0.01% 1276

Other funds holding IRLA

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ergoteles's IRLA Position: Q1 2023 in Review

Ergoteles sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2023, closing a stake of 196 shares — an estimated $25K sold.

Ergoteles first reported a position in IRLA in Q2 2022 and held it in 2 quarters. The position peaked at $218K in Q2 2022. 42 funds tracked by Wall St. Rank hold IRLA as of Q1 2023.

  • Ergoteles reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 196 IRulya Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $25K.
  • Ergoteles first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's IRulya Therapeutics Inc. Common Stock position peaked at $218K in Q2 2022.
  • 42 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.